Amendment to claims:

The following claims have the status of cancelled: 1-49; 61-85; and 93.

Claims 98 and 99 are new and depend from claim 50; Applicant's attorney spoke with Examiner Jones about this addition via a telephone conversation (8/3/04).

Status of the claims:

The status of the claims begins on page 3.

Remarks:

The Remarks section begins on page 6.

1 - 49. (cancelled)

50. (Original) A method of synergistically increasing nitric oxide production by endothelial cells comprising administering a therapeutically effective amount of a combination of amlodipine and an atorvastatin compound selected from the group consisting of atorvastatin and hydroxylated atorvastatin metabolite.

51. (Original) The method of claim 50 wherein amlodipine comprises a therapeutically effective derivative of amlodipine.

52. (Original) The method of claim 50 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

53. (Original) The method of claim 50 wherein the atorvastatin compound comprises a therapeutically effective derivative of the atorvastatin compound.

54. (Original) The method of claim 53 wherein the therapeutically effective derivative of the atorvastatin compound is a hemicalcium salt.

55. (Original) The method of claim 50 wherein amlodipine and the atorvastatin compound are administered in the same therapeutic.

56. (Original) The method of claim 50 wherein amlodipine and the atorvastatin compound are administered as separate therapeutics.

57. (Original) The method of claim 50 wherein amlodipine and the atorvastatin compound are administered at the same time.

58. (Original) The method of claim 50 wherein amlodipine and the atorvastin compound are administered at different times.

59. (Original) The method of claim 50 wherein said pharmaceutical composition synergistically increases nitric oxide production by endothelial cells to an extent consistent with a reduced risk of arterial and related heart disease.

60. (Original) The method of claim 59 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipdemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

61 - 85. (cancelled)

86. (Previously presented) A method of synergistically increasing nitric oxide production by endothelial cells comprising the administration of an effective amount of a combination of amlodipine and atorvastatin.

87. (Previously presented) The method of claim 86, wherein said atorvastatin is a hydroxylated atorvastatin metabolite.

88. (Previously presented) The method of claim 86, wherein said amlodipine and said atorvastatin are administered employing one drug delivery vehicle.

89. (Previously presented) The method of claim 86, wherein said amlodipine and said atorvastatin are administered employing separate drug delivery vehicles.

90. (Previously presented) The method of claim 88, wherein said amlodipine and said atorvastatin are administered at different times.

91. (Previously presented) The method of claims 86, wherein atorvastatin is a hemicalcium salt.

92. (Previously presented) The method of claim 86, wherein amlodipine is a besylate salt.

93. (Cancelled)

94. (Previously presented) The method of claim 86, wherein said amlodipine and said atorvastatin are administered employing one drug delivery vehicle.

95. (Previously presented) The method of claim 86, wherein said amlodipine and said atorvastatin are administered employing separate drug delivery vehicles.

96. (Previously presented) The method of claim 88, wherein said amlodipine and said atorvastatin are administered at different times.

97. (Previously presented) The method of claims 86, wherein atorvastatin is a hemicalcium salt.

98. (New) The method of claim 50, wherein said atorvastatin compound is atorvastatin.

99. (New) The method of claim 50, wherein said atorvastatin compound is hydroxylated atorvastatin metabolite.